Patents by Inventor Per Peterson

Per Peterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220342284
    Abstract: A camera platform track provides running surfaces for independent movement of two or more camera platforms, improves strength to weight ratio, improves torsional rigidity, restricts camera platforms from wandering during filming, and improves traction. The camera platform track includes top running surfaces for a first camera platform, and one or more lower running surfaces for additional camera platforms, allowing desired versatility in filming. The camera platform tracks include a box base and an I-beam reaching up from the base to provide strength and torsional rigidity without excessive weight. The running surface lateral spacing may vary from camera platform wheel spacing providing centering to reduce or eliminate wandering, and may include grooves to improve traction. wandering, and may include grooves to improve traction.
    Type: Application
    Filed: April 20, 2022
    Publication date: October 27, 2022
    Inventor: Per Peterson
  • Patent number: 9247358
    Abstract: A hearing aid includes: a housing having an exterior surface and an opening at the exterior surface; a battery door moveably coupled to the housing; and a spring element located in the housing, wherein the spring element is aligned with the opening of the housing to allow actuation of the spring element by a tool that is inserted through the opening of the housing; wherein when the spring element is actuated by the tool, the battery door is allowed to be fully opened, and when the spring element is un-actuated, the battery door is prevented from being fully opened.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: January 26, 2016
    Assignee: GN RESOUND A/S
    Inventors: Allan Møller Kristensen, Per Peterson
  • Patent number: 9222070
    Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: December 29, 2015
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Didier J. Leturcq, Ann M. Moriarty, Michael R. Jackson, Per A. Peterson, Jon M. Richards
  • Patent number: 9222071
    Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: December 29, 2015
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Ann Moriarty, Didier J. Leturcq, Juli Degraw, Michael R. Jackson, Per A. Peterson, Marja Heiskala
  • Patent number: 8133728
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 13, 2012
    Assignee: Ortho-McNeil Pharmaceutical Corp.
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Patent number: 8133972
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: March 13, 2012
    Assignee: Ortho-McNeil Pharmaceutical Corp.
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Patent number: 8133726
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: March 13, 2012
    Assignee: Ortho-McNeil Pharmaceutical Corp.
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Patent number: 8106153
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: January 31, 2012
    Assignee: Ortho-McNeil Pharmaceutical Corp.
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Patent number: 8084256
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: December 27, 2011
    Assignee: Ortho-McNeil Pharmaceutical Corp.
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Patent number: 8084253
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: December 27, 2011
    Assignee: Ortho-McNeil Pharmaceutical Corp.
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Patent number: 7993638
    Abstract: In a cancer treatment combining cell therapy with chemotherapy, autologous CD8+ T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen-specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in conjunction with a lymphodepletion and CTL maintenance regimen comprising a non-myeloblative but lymphdepleting agent, such as cladribine or denileukin diftitox, and interleukin-2 and interferon-?-2b stimulatory cytokines.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: August 9, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Zeling Cai, Ann Moriarty, Per A. Peterson, Jon M. Richards
  • Publication number: 20110065187
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Application
    Filed: October 6, 2010
    Publication date: March 17, 2011
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Publication number: 20110065186
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Application
    Filed: October 6, 2010
    Publication date: March 17, 2011
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Publication number: 20110065180
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Application
    Filed: October 6, 2010
    Publication date: March 17, 2011
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Publication number: 20110027301
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Application
    Filed: September 21, 2010
    Publication date: February 3, 2011
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Publication number: 20110021747
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Application
    Filed: September 28, 2010
    Publication date: January 27, 2011
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Publication number: 20110020309
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Application
    Filed: September 21, 2010
    Publication date: January 27, 2011
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Publication number: 20110015370
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Application
    Filed: September 28, 2010
    Publication date: January 20, 2011
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Juli DeGraw, Yan Kong
  • Patent number: 7842501
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Grant
    Filed: November 6, 2007
    Date of Patent: November 30, 2010
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw
  • Patent number: 7811816
    Abstract: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: October 12, 2010
    Assignee: Ortho-McNeil Pharmaeutical, Inc.
    Inventors: Zeling Cai, Michael R. Jackson, Per A. Peterson, Wei-Xing Shi, Yan Kong, Juli DeGraw